Dr. Philip A. Hipskind
Chief Executive Officer & Chief Scientific Officer
WHO WE ARE
Discovering Hope for Global Health
Lgenia is dedicated to discovering new medicines to treat tuberculosis, malaria and Alzheimer's disease. Addressing women's health needs is equally important to our overall goal of making affordable treatments available to all patients.
Our Mission
To discover and develop innovative medicines that address the world's most challenging diseases, ensuring no patient is denied access to breakthrough treatments.
Our Vision
A world where every person has access to life-saving medications, regardless of their economic circumstances or geographic location.
Our Research Focus
Targeting four critical areas that impact millions of lives worldwide
Tuberculosis
Developing next-generation anti-TB drugs to combat drug-resistant strains and shorten treatment duration.
- Novel mechanism of action
- Drug-resistant TB focus
- Improved patient compliance
Malaria
Creating innovative antimalarial compounds that target resistant parasites and prevent transmission.
- Transmission blocking
- Resistance prevention
- Single-dose treatments
Alzheimer's Disease
Pioneering neuro-immune targets to slow cognitive decline and preserve quality of life.
- Novel neuro-immune targets
- Early intervention strategies
- Cognitive preservation
Non-Hormonal Contraceptives
Advancing non-hormonal contraceptive discovery to expand reproductive health options and access.
- Women-focused innovation
- Hormone-free approaches
- Broader access and choice
Our History
Our Journey
Key milestones in our mission to discover life-saving medications
2017
Company Founded
Dr. Philip A. Hipskind founded Lgenia Inc. with a vision to make breakthrough medicines accessible to all patients.
2018
TB Drug Accelerator Partnership
Became a collaborating organization of the TB Drug Accelerator, supported by the Bill and Melinda Gates Foundation.
2019
TREAT AD Collaboration
Strategic partnership with Indiana University's NIH-sponsored TREAT-AD Center for Alzheimer's disease research.
2020
Malaria Drug Accelerator
Expanded partnership to include the Malaria Drug Accelerator program for antimalarial drug discovery.
2025
Non-Hormonal Contraceptives
Added a new discovery program focused on non-hormonal contraceptives to broaden our reproductive health portfolio.
Meet Our Research Leadership
World-class scientists dedicated to discovering life-saving medications
Dr. Cynthia D. Jesudason
Senior Portfolio Director
Dr. David Mendel
Senior Portfolio Director
Karen Lobb
Senior Portfolio Director
Leonard Winneroski
Senior Portfolio Director
Dr. Miles Siegel
Senior Portfolio Director
Dr. Kenn Henry
Senior Portfolio Director
Greg Durst
Senior Portfolio Director
Elizabeth Aaron
Director of Research Operations
Our Core Values
The principles that guide our research and development efforts
Excellence
Pursuing the highest standards in scientific research and drug development to deliver breakthrough therapies.
Accessibility
Ensuring that life-saving medications are available and affordable to patients regardless of their circumstances.
Compassion
Driven by empathy for patients and families affected by devastating diseases that need better treatment options.
Collaboration
Building partnerships with leading institutions and organizations to accelerate medical breakthroughs.